Skip to content

International COVID-19 Clinical Evaluation Registry -2 (HOPE-2)

International COVID-19 Clinical Evaluation Registry -2 (HOPE-2)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04778020
Acronym
HOPE-2
Enrollment
9299
Registered
2021-03-02
Start date
2021-03-01
Completion date
2022-01-10
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

PURPOSE. The main objective of the present study is to carefully characterize the clinical profile of individuals with lasting sequelae after a COVID-19 admission. As secondary objectives, the analysis of the risk-adjusted influence of COVID-19 severity, previous comorbidities and management of patients discharged after COVID-19 will be performed. DESIGN AND STATISTICAL ANALYSIS Cross-sectional and prospective registry, a real life all comers type, with voluntary participation, without specific funding or conflicts of interest. It is a study initiated by researcher that will have advanced statistical support from the IMAS foundation (Institute for the Improvement of Health Care, Madrid, Spain) and the Cardiovascular Research Foundation (FIC, Madrid, Spain). International level. PARTICIPANTS PROTOCOL. The study has been approved by Hospital Clinico San Carlos Ethic´s Committee (21/128-E) and the institutional board of each participating center. The present study proposes the continuation in time of the work previously carried out in the HOPE registry. It proposes to select all the patients attended in any health center (with in hospital beds), who have been discharged or have died up to 31st august 2020. All will be considered eligible with a positive COVID-19 test (any type) or if their attending physicians consider them highly likely to have presented the infection. Given the anonymous characteristics of the registry and the health alarm situation generated by the virus, in principle, it is not considered necessary to provide written informed consent.

Interventions

None listed

Sponsors

St Carlos Hospital, Madrid, Spain
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients discharged (deceased or alive) from any hospital center with a confirmed diagnosis.

Exclusion criteria

* There are no

Design outcomes

Primary

MeasureTime frameDescription
DEATHthrough study completion, an average of 1 yearNumber of participants dead by any cause during follow up.

Secondary

MeasureTime frameDescription
Any POSTCOVID-19 symptomthrough study completion, an average of 1 yearEvents defined in HOPE 2 protocol

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026